Brazilian Association of Pharmaceutical Inputs Industry trusts that director Thiago Campos' request for review will result in a more thorough analysis, maintaining the expectation of regulatory framework completion in January 2026

Initiative complies with State Law 8,754/22 and aims to prepare professionals to prescribe cannabis safely and legally

Anvisa authorizations for importing cannabidiol in São Paulo increased by 6.2% between January and July 2025, consolidating the state as a leader in requests and reflecting the expanded access through the SUS

Understand the step-by-step process to acquire plant derivatives for medicinal purposes

Resumption of Anvisa review and STJ deadline for cultivation define the sector's direction in the first quarter of the year

The event brings together experts, companies, and authorities to discuss regulatory advances, research, and innovation in cannabis-based therapies, connecting the entire public and private sector

Debates on medicinal cannabis continue deeply at Cannabis Connection 2025 in November and at the Brazilian Medicinal Cannabis Congress in May 2026, both in São Paulo.

COFFITO Ruling No. 735/2024 authorizes physical therapists with specific training to prescribe medications and supplies; however, Anvisa recognizes only doctors and dentists as prescribers of cannabis for medicinal purposes

Learn How to Access Cannabis Products Through the Unified Health System and Understand the Obligations of Health Insurance Providers

Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027

Submission of registrations, videos, and requests for confidentiality ends at 11:59 pm this Friday (5); item revising rules for cannabis products will be defined at the Dicol meeting on December 10

Anvisa's update "mirrors" the rules for controlling cannabis products directly in the list of controlled substances and defines classification for industrial inputs

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence

On Deusa Cast, lawyer Larissa Meneghel details how the five-year deadline set forth in RDC-327 for clinical cannabis research works and comments on the renewal proposal under review by Anvisa

The item revising RDC 327/2019 reaches a decisive week at Anvisa, and the sector awaits to know if the topic will proceed to a vote or be postponed once again

Norm that regulates manufacturing, importation, prescription, and inspection may be entirely revoked and replaced by a new regulatory framework; decision will be made at the Collegiate Board meeting.

Draft presents new regulatory framework, tightens requirements for Sanitary Authorization, and prohibits manipulation of cannabis derivatives

Caroline Campagnone views RDC 999/2025 favorably, allowing veterinarians authorized by CFMV to prescribe medical cannabis

With the revision of RDC 327/2019, compounding pharmacies gain space in the discussion on medicinal cannabis

Marcelo Mario Matos Moreira takes over as substitute in the Fourth Board, filling the vacancy of the former rapporteur of the review of RDC 327